INSIGHTS
No marketing stories — only the facts patients actually need to verify: which treatments are available in China, how long they take, what they cost, and where the pathway most often breaks.
Four CAR-T products are approved in China, covering lymphoma, leukaemia and multiple myeloma. This note covers eligibility, assessment criteria, manufacturing timeline, cost ranges and key risks.
Read the noteNeither is simply "better photon therapy" — both are particle beams. The choice depends on tumour location, nearby organs at risk, prior radiotherapy and long-term risk in children.
Read the noteFour steps, how long each takes, the documents required, visa types and common pitfalls.
Read the noteForeign patients worry about three things: credentials, complication management and dispute resolution. This note explains how Chinese oncology care is regulated, which hard indicators we verify, and what patients can check themselves.
Read the noteCost differences come from three blocks: technology and drugs, hospital and service charges, and coordination fees. This note gives published ranges by therapy and lists the extra costs most often missed.
Read the noteChina has no standalone medical visa category; treatment trips are made under a medical-purpose entry. This note walks through the invitation letter, application documents, in-country stay permits and the usual sticking points in order.
Read the noteMost patients need a written opinion they can show their local doctor before deciding to travel. This note covers what to submit, what arrives within 24–48 hours, and what a remote opinion cannot replace.
Read the noteCross-border record transfer risks come mainly from the channel chosen and from over-sharing. This note gives practical rules: what to send, what not to, which channel, and how to withdraw consent.
Read the noteProtons and carbon ions are not simply “better radiotherapy” — they suit specific anatomical sites and stages. This note covers who benefits, common misconceptions and Shanghai’s published outcomes.
Read the noteBNCT is among the most discussed new radiotherapy techniques, but it remains in registration trials. This note covers the mechanism, current access, candidate criteria, and the marketing language to be wary of.
Read the noteChina runs one of the world’s largest portfolios of oncology trials, but being able to apply is not the same as being eligible. This note covers the practical barriers for foreign nationals, who pays, and what informed consent should include.
Read the noteChina offers domestic PD-1 agents and bispecifics alongside overseas medicines brought in through Boao Lecheng. This note explains access routes, why prices differ, and three ways to verify authenticity.
Read the noteFree case review